

Sentrex Health Solutions Inc.

Report pursuant to the Fighting Against Forced Labour and Child Labour in Supply Chains Act (the “Act”) for the financial year ended October 31, 2025.

1. INTRODUCTION

This report is made by Sentrex Health Solutions Inc. (“**Sentrex**”), on behalf of itself and its subsidiaries, Sentrex Distribution Inc. (“**SDI**”) and Sentrex Pharmacy Group Inc. (“**SPG**”), each as reporting entities under the Act referenced above. The report also covers Sentrex's controlled entity PerCuro Clinical Research Ltd. (“**PCR**”), which does not separately meet the reporting threshold under the Act but whose activities are included for completeness. This report applies to Sentrex, SDI, SPG and PCR as a whole.

In preparing this joint report, Sentrex's legal, compliance and procurement functions consulted with senior management of each reporting entity and PCR to confirm activities, supply chain composition, due-diligence practices and training delivered during the reporting period. Information was gathered from internal policies and procedures, vendor records, training records, and outputs of the Vendor Assessment Questionnaire described in section 3.

2. STRUCTURE, ACTIVITIES AND SUPPLY CHAINS

(a) Structure

Sentrex is a private company incorporated under the *Business Corporations Act* (Ontario). SDI and SPG are controlled subsidiaries of Sentrex, each also incorporated under the *Business Corporations Act* (Ontario). PCR is a controlled subsidiary of Sentrex, incorporated under the *Business Corporations Act* (British Columbia). PCR provides clinical research services and does not produce or import goods; it is included in this report for completeness as a Sentrex-controlled entity.

(b) Activities

Sentrex is a fully integrated specialty pharmaceutical distributor and patient support provider for pharmaceutical manufacturers, physicians and their patients. SPG focuses on the provision of specialty pharmacy services, including cold chain biologics, sterile compounding, temperature sensitive logistics and novel drug delivery systems in the areas of ophthalmology, oncology, neurology, respiratory and rare diseases. SDI provides storage and distribution services for specialty pharmaceuticals from a state-of-the-art GMP-compliant facilities located in Markham (ON). In addition, Sentrex provides specialty pharmacy services in Windsor (ON), Vancouver (BC), Calgary (AB), Moncton (NB), Halifax (NS), Charlottetown (PEI) and Corner Brook (NL).

(c) Supply Chains

Sentrex sources pharmaceuticals and medical devices from Canadian pharmaceutical companies or the Canadian subsidiary of international pharmaceutical companies, as well as from certain non-Canadian

companies, located in Switzerland, Israel, and the United States. Each of these source jurisdictions is generally regarded as low-risk for forced labour and child labour based on indices such as the U.S. Department of State's Trafficking in Persons Report and the Walk Free Global Slavery Index. Sentrex's direct suppliers in these jurisdictions are established pharmaceutical manufacturers subject to extensive regulatory oversight in their home countries.

3. POLICIES AND DUE DILIGENCE PROCESSES IN RELATION TO FORCED LABOUR AND CHILD LABOUR

Sentrex has a robust Code of Conduct in place to which all employees must strictly adhere. Included in the Code of Conduct are sections on Business Ethics and Conduct, Anti-Bribery and Anti-Corruption, and a Whistleblower policy. In addition, Sentrex has implemented a Vendor Assessment Questionnaire which includes specific questions about whether the organization in question has documented policies and procedures in place relating to human rights, including policies and procedures to assess, report and respond to risks of forced labour or child labour, and requiring suppliers to describe the nature of the goods and the source countries and/or suppliers of materials used in the production of the goods. Sentrex includes contractual provisions in its agreements requiring compliance with Canadian laws, including the Act. Oversight of Sentrex's forced labour and child labour program rests with senior management, with operational implementation supported by the procurement, legal, and compliance functions. Material concerns may be escalated through Sentrex's Whistleblower policy and are reviewed by senior management. The Whistleblower policy permits anonymous reporting and is available to employees and, on request, to suppliers and other stakeholders. Reports received through the Whistleblower channel are triaged by the Chief Legal Officer and may be escalated to senior management or the Board of Directors depending on severity. No reports relating to forced labour or child labour were received during the financial year ended October 31, 2025.

4. PARTS OF BUSINESS AND SUPPLY CHAINS THAT CARRY A RISK OF FORCED LABOUR AND CHILD LABOUR AND STEPS TAKEN TO ASSESS AND MANAGE THAT RISK

Sentrex assesses its business and supply chain for risks of forced labour and child labour as an ongoing procedure. As described in section 2(c), Sentrex's pharmaceutical goods are sourced from suppliers in Canada and in jurisdictions (Switzerland, Israel, and the United States) generally regarded as low-risk for forced labour and child labour, and its direct suppliers are established pharmaceutical manufacturers subject to extensive regulatory oversight. Notwithstanding this risk profile, Sentrex has taken the following steps to assess and manage risk on an ongoing basis:

- (a) updating and implementing a Vendor Assessment Questionnaire that includes specific questions regarding the source of goods supplied to Sentrex and requires suppliers to confirm documented policies and procedures relating to human rights, including policies and procedures to assess, report and respond to risks of forced labour or child labour; and
- (b) updating its contract review process to expressly require suppliers to comply with the Act.

Sentrex's risk-assessment activities are kept under ongoing review and are expanded as new risks are identified.

Frequency. Sentrex conducts a forced labour and child labour risk assessment on at least an annual basis, in connection with the preparation of this report, and on an ad hoc basis when new suppliers are onboarded or when changes in supply chain composition or relevant external indices warrant a refreshed assessment.

Governance. Responsibility for the risk assessment rests with Sentrex's Chief Legal Officer, VP, Specialty Operations, and VP, Quality and Patient Safety, working with the procurement and vendor-management functions. Findings are reported to senior management.

Methodology and information sources. Sentrex identifies and assesses risk using: (i) desk-based research and country-level indices, including the U.S. Department of State Trafficking in Persons Report and the Walk Free Global Slavery Index; (ii) the Vendor Assessment Questionnaire described in section 3; (iii) review of supplier-provided documentation regarding their human rights policies and procedures; and (iv) reports received through Sentrex's Whistleblower policy.

Highest-priority risks. Based on the risk assessment described above, Sentrex has not identified any high-priority risks of forced labour or child labour in its direct (Tier 1) supply chain. Lower-tier supply chain risk is being assessed on a prioritized basis as Sentrex extends its due diligence beyond Tier 1.

5. MEASURES TAKEN TO REMEDIATE FORCED LABOUR AND CHILD LABOUR

Sentrex has not identified instances of forced labour or child labour in its business or supply chains.

Due diligence approach. Sentrex's human rights due diligence approach is implemented through (i) the Vendor Assessment Questionnaire, completed by new suppliers and refreshed periodically for existing suppliers; (ii) contract review processes that require suppliers to comply with applicable laws including the Act; (iii) ongoing monitoring of supplier-related adverse media; and (iv) reports received through Sentrex's Whistleblower policy. Responsibility for the due diligence program rests with senior management, with operational support from the procurement, legal and compliance functions.

Scope. Sentrex's supplier due diligence currently covers its direct (Tier 1) suppliers. Sentrex is extending its risk assessment to lower-tier suppliers on a prioritized basis as part of the continuous improvement of its program.

Remediation. Sentrex's existing remediation framework provides for, in the event that an allegation or instance of forced labour or child labour is identified: (i) prompt investigation, including engagement with the supplier and, where appropriate, third parties; (ii) corrective action, which may include enhanced supplier due diligence, requirements for supplier remediation plans, or termination of the supplier relationship; and (iii) escalation to senior management and, where warranted, the Board of Directors. No instances of forced labour or child labour were identified in the financial year ended October 31, 2025, and accordingly no remediation steps were required.

6. MEASURES TAKEN TO REMEDIATE LOSS OF INCOME TO MOST VULNERABLE FAMILIES THAT RESULT FROM MEASURES TAKEN TO ELIMINATE USE OF FORCED LABOUR AND CHILD LABOUR

Because Sentrex has not identified any instances of forced labour or child labour in its business or supply chains, it has not taken measures to eliminate such use or to remediate any loss of income to vulnerable families during the financial year ended October 31, 2025.

7. TRAINING PROVIDED TO EMPLOYEES ON FORCED LABOUR AND CHILD LABOUR

Sentrex maintains a mandatory, recurring training program covering Business Ethics and Conduct, Anti-Bribery and Anti-Corruption, and Canadian human rights legislation. The program addresses the principles underlying the prohibition of forced labour and child labour and the role of employees in escalating concerns through Sentrex's Whistleblower policy. New employees complete the training as part of onboarding, and all employees recertify annually.

During the financial year ended October 31, 2025, Sentrex's training program expressly incorporated the requirements of the Act, including the section 2 definitions of forced labour and child labour, indicators of forced labour and child labour in supply chains, and supplier due-diligence escalation pathways. Targeted supplemental training was provided to employees in procurement, vendor management, and legal functions, given their direct role in supplier due diligence.

8. HOW ENTITY ASSESSES ITS EFFECTIVENESS IN ENSURING THAT FORCED LABOUR AND CHILD LABOUR IS NOT BEING USED IN ITS BUSINESS AND SUPPLY CHAINS

Sentrex assesses the effectiveness of its forced labour and child labour program by reference to multiple inputs, including (i) annual review of policies and procedures relating to forced labour and child labour, (ii) supplier due-diligence outputs from the Vendor Assessment Questionnaire and contract review processes, (iii) internal and, where warranted, external audits and supplier site reviews, (iv) adverse media monitoring of suppliers, and (v) reports received through Sentrex's Whistleblower policy. Sentrex has not identified, through any of these inputs, instances of forced labour or child labour in its business or supply chains during the financial year ended October 31, 2025. Sentrex continues to refine this framework consistent with the continuous-improvement approach contemplated by the Act and Public Safety Canada's guidance, and intends to expand the indicators reported in future annual reports.

9. OTHER RELEVANT INFORMATION

Challenges. The principal challenges Sentrex faces in responding to the Act's requirements relate to obtaining visibility into lower-tier (sub-Tier 1) supply chains and to harmonizing due-diligence inputs across a supplier base composed predominantly of large, regulated pharmaceutical manufacturers operating in low-risk jurisdictions. Sentrex addresses these through the supplier-engagement and risk-assessment processes described above and through ongoing review of available external data sources.

ATTESTATION

This report has been approved by the Board of Directors of Sentrex Health Solutions Inc., on its own behalf and on behalf of the other reporting entities.

This is a joint report. It was approved pursuant to subparagraph 11(4)(b)(ii) of the Act by the governing body of Sentrex Health Solutions Inc., the entity that controls each other entity to which the report relates.

In accordance with the requirements of the Act, and in particular section 11 thereof, I, in the capacity of Founder & President of Sentrex Health Solutions Inc., attest that I have reviewed the information contained in the report on behalf of the governing body of each entity listed above. Based on my knowledge, and having exercised reasonable diligence, I attest that the information in the report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed within this report.

Signature:

Signed by Joe Connolly



I approve this document
25-May-2026 | 1:33:15 PM EDT

Name: Joe Connolly
C7F612581A8742C191476B2708FD3689

Title: Founder & President

I have authority to bind Sentrex Health Solutions Inc., Sentrex Distribution Inc., Sentrex Pharmacy Group Inc., and PerCuro Clinical Research Ltd.

Date: May 31, 2026